Physician profile
Kora L Smith
NPI 1063908929
$3,011.49
in general payments reported to CMS, 2019-2025
19 companies · $717 in 2025
The $717 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $47.19 · 2021: $332 · 2022: $315 · 2023: $126 · 2024: $900 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,543 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,543.13 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $526.82 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $496.98 | 2022-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $286.32 | 2019-2024 | Cequa |
| Alcon Vision LLC | $279.74 | 2019-2025 | Rocklatan, Tryptyr, Precision 1 |
| Kala Pharmaceuticals, INC. | $264.88 | 2019-2021 | |
| Oyster Point Pharma, INC. | $224.05 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Allergan, INC. | $206.69 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $140.99 | 2024-2025 | Xiidra, Miebo, Vyzulta |
| Abbvie INC. | $140.32 | 2022-2025 | Lumigan |
| Dompe US, INC. | $118.25 | 2024-2025 | Oxervate |
| Lensar, INC. | $99.98 | 2021 | |
| Novartis Pharmaceuticals Corporation | $64.57 | 2020-2023 | |
| Biotissue Holdings INC. | $36.65 | 2019-2021 | |
| Harrow Eye, LLC | $30.49 | 2024-2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $24.33 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $22.23 | 2019 | |
| Amgen INC. | $19.74 | 2025 | Tepezza |
| New World Medical,INC. | $14.70 | 2022 | |
| Tearlab Corp | $13.76 | 2024 | Scoutpro Osmolarity System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kora Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.